ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Journal of Hepatocellular Carcinoma · 2025-04 · Volume 12 · 671-683
DOI: 10.2147/jhc.s462701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-04. Verfasst von Bernardo Stefanini und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, London, UK. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Background and Aims: Atezolizumab and bevacizumab (A+B) are recommended for treating unresectable hepatocellular carcinoma (HCC). Although highly effective, A+B can lead to potentially life-threatening adverse events including bleeding. We investigated whether albumin-bilirubin (ALBI) grade identifies patients with a higher risk of bleeding and its impact on prognosis than the Child-Pugh (CP) score.
Methods
We performed a multicenter retrospective study of 15 tertiary referral centers that consecutively treated patients with A+B. We analyzed the association between the ALBI grade and gastrointestinal bleeding using the χ2 test. Overall survival (OS) stratified by ALBI was estimated using the Kaplan-Meier method and the predictive value for the 6-months OS landmark with ROC curves.
Results
Of the 368 patients included in the analysis, 163 (44.3%), 192 (52.2%) and 13 (3.5%) had ALBI 1, ALBI 2, and ALBI 3, respectively. ALBI grade was associated with a 3-fold increase in bleeding risk (3.1% in ALBI 1 vs 10.2% in ALBI 2/3, p=0.008). Among 192 patients with pre-treatment EGD, G2 and G3 varices were associated with an increased risk of bleeding, whereas G1 varices had a similar risk as no varices. Patients with ALBI 1 achieved a longer median OS (not reached; 95% CI, 24.9-33.7), than ALBI 2 (9.7 months; 95% CI, 7.0-12.3) or ALBI 3 (5.6 months; 95% CI, 0.1-12.0). ALBI outperformed the CP score for predicting 6-month OS with an AUC 0.79 of ALBI versus 0.71 for the CP score (p=0.01).
Conclusion
A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London, London, UK.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
- Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
ORCID-Profile: Lorenza Rimassa, Tiziana Pressiani, Lorenz Balcar, Aman Mehan, Peter R Galle, Masatoshi Kudo, Hong Jae Chon, Fabio Piscaglia, David James Pinato, Antonio D'Alessio
Förderung
- Wellcome Trust
Zitieren
APA
Stefanini, B., Fulgenzi, C. A. M., Scheiner, B., Korolewicz, J., Cheon, J., Nishida, N., Ang, C., Marron, T. U., Wu, Y. L., Saeed, A., Wietharn, B., Rimassa, L., Pirozzi, A., Cammarota, A., Pressiani, T., Pinter, M., Balcar, L., Huang, Y. H., Mehan, A., …, & D'Alessio, A. (2025). ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab. Journal of Hepatocellular Carcinoma, Volume 12, 671-683. https://doi.org/10.2147/jhc.s462701
Vancouver
Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, et al. ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab. Journal of Hepatocellular Carcinoma. 2025;Volume 12:671-683. doi:10.2147/jhc.s462701
BibTeX
@article{Stefanini2025,
author = {Stefanini, Bernardo and Fulgenzi, Claudia Angela Maria and Scheiner, Bernhard and Korolewicz, James and Cheon, Jaekyung and Nishida, Naoshi and Ang, Celina and Marron, Thomas U and Wu, Y Linda and Saeed, Anwaar and Wietharn, Brooke and Rimassa, Lorenza and Pirozzi, Angelo and Cammarota, Antonella and Pressiani, Tiziana and Pinter, Matthias and Balcar, Lorenz and Huang, Yi-Hsiang and Mehan, Aman and Phen, Samuel and Vivaldi, Caterina and Salani, Francesca and Masi, Gianluca and Bettinger, Dominik and Vogel, Arndt and Schönlein, Martin and von Felden, Johann and Schulze, Kornelius and Wege, Henning and Samson, Adel and Galle, Peter R and Kudo, Masatoshi and Manfredi, Giulia Francesca and Celsa, Ciro and Awosika, Nichola and Cortellini, Alessio and Singal, Amit G and Sharma, Rohini and Chon, Hong Jae and Tovoli, Francesco and Piscaglia, Fabio and Pinato, David James and D'Alessio, Antonio},
title = {ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab},
journal = {Journal of Hepatocellular Carcinoma},
year = {2025},
volume = {Volume 12},
pages = {671--683},
doi = {10.2147/jhc.s462701}
}
EUVIMED